News & Videos - NOVAVAX INC. - Page 2

Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S. PR Newswire GAITHERSBURG, Md., Sept. 13, 2024 Doses of Novavax's 2024-2025 Formula COVID-19 vaccine now available at thousands of locations nationwide Novavax's updated vaccine is the only protein-based option available in the U.S. this fall for individuals aged 12 and older GAITHERSBURG, Md. , Sept. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with...

Novavax to Participate in Upcoming September Conferences PR Newswire GAITHERSBURG, Md., Sept. 4, 2024 GAITHERSBURG, Md. , Sept. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in two upcoming investor conferences. H.C. Wainwright 26 th Annual Global Investment Conference: Fireside Chat Date: Monday, September 9, 2024 Time: 3:30 – 4:00 p.m. Eastern Time (ET)...

Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. PR Newswire GAITHERSBURG, Md., Aug. 30, 2024 Novavax expects pre-filled syringes will be broadly available in thousands of locations across the U.S. Novavax's vaccine is the only protein-based option available in the U.S. for use in individuals aged 12 and older to prevent COVID-19 GAITHERSBURG, Md. , Aug. 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based...

Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights PR Newswire GAITHERSBURG, Md., Aug. 8, 2024 Achieved total revenue of $415 million in the second quarter of 2024 and ended the period with $1.1 billion in Cash Filed with the U.S. FDA and EMA for authorization of updated 2024-2025 formula COVID-19 vaccine Received $570 million in upfront payment and equity investment from Sanofi; progressed operationalization of Sanofi partnership Phase 3 trial initiation for...

Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024 PR Newswire GAITHERSBURG, Md., Aug. 1, 2024 GAITHERSBURG, Md. , Aug. 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its second quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, August 8, 2024 . Details...

Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine PR Newswire GAITHERSBURG, Md., June 24, 2024 Novavax's JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 GAITHERSBURG, Md. , June 24, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has filed for a type II variation of existing...

Novavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine PR Newswire GAITHERSBURG, Md., June 14, 2024 Novavax's updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 Novavax's JN.1 COVID-19 vaccine would be the only protein-based option available in the U.S. Novavax's filing is aligned with FDA, EMA and WHO global recommendations on vaccine composition Novavax intends to have its vaccine in pre-filled...

Novavax to Participate in 2024 Jefferies Global Healthcare Conference PR Newswire GAITHERSBURG, Md., May 30, 2024 GAITHERSBURG, Md. , May 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference. Conference Details: Fireside Chat Date: Thursday, June 6, 2024 Time: 12:30 – 12:55 p.m. Eastern Time (ET) Location: New York, NY...

Novavax to Participate in BofA Securities 2024 Health Care Conference PR Newswire GAITHERSBURG, Md., May 13, 2024 GAITHERSBURG, Md. , May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, May 15, 2024 Time: 3:00 – 3:30 p.m. Pacific Daylight Time (PDT) Location: Encore...

Novavax Reports First Quarter 2024 Financial Results and Operational Highlights PR Newswire GAITHERSBURG, Md., May 10, 2024 Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-M TM adjuvant This agreement represents a potential multi-billion dollar revenue opportunity for Novavax including : $500 million upfront payment Approximately $70...

Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines PR Newswire GAITHERSBURG, Md., May 10, 2024 Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Provides Novavax with cash and an equity investment totalling approximately $1.2 billion (upfront payment of $500 million and up to $700...

Novavax to Host Conference Call to Discuss First Quarter 2024 Financial Results and Operational Highlights on May 10, 2024 PR Newswire GAITHERSBURG, Md., May 7, 2024 GAITHERSBURG, Md. , May 7, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its first quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Friday, May 10, 2024 . Details of the...

Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024 PR Newswire GAITHERSBURG, Md., April 1, 2024 GAITHERSBURG, Md. , April 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will showcase continued progress on data from its updated COVID-19 vaccine (NVX-CoV2601) and provide an overview of its influenza and...

Novavax to Participate in TD Cowen's 44th Annual Health Care Conference PR Newswire GAITHERSBURG, Md., Feb. 29, 2024 GAITHERSBURG, Md. , Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen's 44 th Annual Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, March 6, 2024 Time: 1:30 – 2:00 p.m. Eastern Standard Time (EST) Location: Boston...

Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights PR Newswire GAITHERSBURG, Md., Feb. 28, 2024 Achieved revenues in Q4 2023 of $291 million and full year 2023 of $1.0 billion Accelerating progress toward expanding pipeline via Phase 3 COVID-19-Influenza Combination vaccine trial in second half 2024 and potential 2026 launch Rescaled global footprint with 30% total headcount reduction as compared to Q1 2023 Announced settlement with Gavi related to...

Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement PR Newswire GAITHERSBURG, Md. and GENEVA, Feb. 22, 2024 GAITHERSBURG, Md. and GENEVA , Feb. 22, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) and Gavi, the Vaccine Alliance (Gavi) today announced they have reached a settlement related to the 2021 Advance Purchase Agreement (APA) for Novavax's prototype COVID-19 vaccine (NVX-CoV2373). This agreement brings the pending arbitration related to the APA to a...

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024 PR Newswire GAITHERSBURG, Md., Feb. 20, 2024 GAITHERSBURG, Md. , Feb. 20, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time...

Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire GAITHERSBURG, Md., Jan. 3, 2024 GAITHERSBURG, Md. , Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42 th Annual J.P. Morgan Healthcare Conference. Conference Details: Presentation and Q&A Date: Monday, January 8, 2024 Time: 5:15 – 5:55 p.m. Pacific Standard Time (PST)...

Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan PR Newswire GAITHERSBURG, Md., Dec. 18, 2023 Novavax's updated vaccine will be available at vaccination centers across Taiwan GAITHERSBURG, Md. , Dec. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M ™ adjuvant, today announced that the Taiwan Food and Drug Administration has granted emergency use authorization for Nuvaxovid ™ XBB.1.5...

Novavax's Updated COVID-19 Vaccine Now Authorized in Canada PR Newswire GAITHERSBURG, Md., Dec. 5, 2023 Novavax's updated protein-based non-mRNA COVID-19 vaccine will be available in Canada for individuals aged 12 and older in the coming days GAITHERSBURG, Md. , Dec. 5, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M ™ adjuvant, today announced that Health Canada has granted expanded authorization for Nuvaxovid™ XBB.1.5...